Thyroid Hormone Receptor-β Agonists: How to Select the Right Agent

What Is the THR-β Agonist Drug Class?

THR-β agonists are small molecules that selectively activate thyroid hormone receptor isoform beta over isoform alpha. The liver expresses predominantly THR-β, while the heart and bone express predominantly THR-α. This isoform distribution is the pharmacologic rationale for the class: you can drive hepatic lipid oxidation and reduce LDL-C without the tachycardia, arrhythmia risk, or bone-resorbing effects of non-selective thyromimetics.

Receptor Biology That Drives Clinical Decision-Making

Thyroid hormone receptors are nuclear receptors. When a THR-β agonist enters a hepatocyte, it binds THR-β, forming a heterodimer with retinoid X receptor (RXR), and activates thyroid hormone response elements (TREs) on target genes. The net hepatic effect is increased fatty acid oxidation, decreased lipogenesis, reduced apolipoprotein B secretion, and upregulation of SR-BI (scavenger receptor class B type I), which accelerates reverse cholesterol transport [1].

This mechanism directly addresses the two dominant pathologic drivers of MASH: hepatic steatosis and dyslipidemia.

Why Selectivity Matters in Practice

Non-selective thyroid hormone excess causes atrial fibrillation, accelerated bone turnover, and muscle catabolism. Earlier thyromimetics like DITPA and CGS-23425 failed development partly because of insufficient THR-β selectivity. Resmetirom demonstrates greater than 28-fold selectivity for THR-β over THR-α in binding assays, and its liver-first pharmacokinetics, driven by active hepatic uptake via organic anion-transporting polypeptides (OATPs), further reduce systemic THR-α exposure [2].

The MAESTRO-NASH trial cardiac monitoring data showed no statistically significant difference in atrial fibrillation incidence between resmetirom 80 mg (1.5%), resmetirom 100 mg (2.0%), and placebo (1.8%), consistent with the selectivity profile [3].

Resmetirom: The Reference Agent

Resmetirom is the prototype and currently the only commercially available THR-β agonist. The FDA granted accelerated approval on March 14, 2024, based on surrogate endpoints (histologic NASH resolution and fibrosis improvement), with full approval contingent on cardiovascular outcomes and cirrhosis-prevention data from ongoing extensions of MAESTRO-NASH.

MAESTRO-NASH Trial Design and Results

MAESTRO-NASH was a Phase 3, randomized, double-blind, placebo-controlled trial enrolling 966 adults with biopsy-confirmed NASH (now reclassified as MASH) and fibrosis stage F1B through F4 [3]. Patients were randomized 1:1:1 to resmetirom 80 mg, resmetirom 100 mg, or placebo for 52 weeks, with a second liver biopsy at week 52.

Co-primary endpoints were:

• NASH resolution (NAS activity score <1 for hepatocellular ballooning, <1 for lobular inflammation) with no worsening of fibrosis
• Fibrosis improvement of at least one stage with no worsening of NASH activity

At 52 weeks [3]:

| Endpoint | 80 mg | 100 mg | Placebo | |---|---|---|---| | NASH resolution | 29.9% | 25.9% | 9.7% | | Fibrosis improvement ≥1 stage | 24.2% | 25.9% | 14.2% |

Both doses met both co-primary endpoints with P<0.001 versus placebo. The number needed to treat for NASH resolution at 80 mg is approximately 5.

Secondary Endpoints Worth Knowing

LDL-C fell by 13.6% from baseline with 80 mg and 16.3% with 100 mg at week 24, versus a 0.1% rise with placebo [3]. Apolipoprotein B decreased by approximately 14% and triglycerides by roughly 23% with the 100 mg dose. These lipid effects have drawn interest in using resmetirom for patients with both MASH and mixed dyslipidemia, though the current label restricts use to the MASH indication.

The FDA's medical review briefing document notes that "the magnitude of fibrosis improvement observed with resmetirom is clinically meaningful given the limited therapeutic options for patients with MASH and advanced fibrosis" [4].

Dosing and Administration

Standard Dosing Protocol

The FDA-approved dosing for resmetirom is [4]:

• 80 mg orally once daily as the initial dose for most patients
• 100 mg orally once daily for patients who weigh 100 kg or more, or for patients who do not achieve adequate lipid response on 80 mg after 12 weeks

The tablet is taken with food. Co-administration with a high-fat meal reduces peak concentration (Cmax) but not overall exposure (AUC), so consistent food intake reduces gastrointestinal side effects without meaningfully altering efficacy.

Dose Adjustments for Hepatic Impairment

Resmetirom is a liver-targeted drug used in patients with hepatic fibrosis. The prescribing information contraindicates use in decompensated cirrhosis (Child-Pugh B or C) [4]. No dose adjustment is required for Child-Pugh A. For patients with compensated cirrhosis (F4), the MAESTRO-NASH trial enrolled F1B through F4 patients, but F4 patients comprised a small subgroup; prescribers should weigh benefit-risk individually and monitor LFTs at baseline, 3 months, and 6 months.

Drug Interactions: The CYP and OATP Field

Resmetirom is a substrate of CYP2C8 and OATP1B1/1B3. Three interaction categories demand attention at the prescribing level [4]:

CYP2C8 Inhibitors

Strong CYP2C8 inhibitors (gemfibrozil, clopidogrel administered as a loading dose) increase resmetirom AUC by approximately 2-fold. The label recommends avoiding strong CYP2C8 inhibitors. If co-administration is unavoidable, reduce resmetirom to 80 mg regardless of weight. Gemfibrozil is particularly relevant because prescribers treating MASH with mixed dyslipidemia may reach for fibrates simultaneously.

OATP Inhibitors

Rifampicin (single dose) increases resmetirom Cmax by 105% via OATP inhibition. Cyclosporine, a potent OATP1B1/1B3 inhibitor, is contraindicated with resmetirom per the label [4].

Statin Interactions

Resmetirom is a mild inhibitor of OATP1B1 and may increase statin exposure. In MAESTRO-NASH, approximately 56% of patients were on background statin therapy without excess myopathy signals. For rosuvastatin (an OATP substrate), the FDA review suggests monitoring at standard clinical intervals rather than a blanket dose cap, but prescribers should document baseline CK if concerns arise [3].

Selecting the Right Agent Within the Class

As of early 2025, the agent-selection question within the THR-β agonist class is largely a binary: resmetirom versus nothing, because no other agent has regulatory approval. The practical selection framework therefore addresses three scenarios.

Scenario 1: MASH F2-F3, No Cirrhosis

This is the labeled sweet spot. Start at 80 mg. Reassess LFTs at 3 months. If the patient weighs 100 kg or more and tolerates 80 mg without significant GI symptoms, consider escalating to 100 mg at 12 weeks based on lipid response. Repeat imaging (MRI-PDFF) at 6 months is not required per label but provides an objective steatosis response marker.

Scenario 2: MASH F4 (Compensated Cirrhosis)

Resmetirom is not contraindicated in compensated cirrhosis, but this population was underrepresented in MAESTRO-NASH. The American Association for the Study of Liver Diseases (AASLD) guidance notes that patients with F4 MASH have the highest unmet need but also the narrowest safety margin for hepatotoxic drug exposure [5]. Monitor AST/ALT at baseline, month 1, month 3, and every 6 months. Discontinue if ALT exceeds 3 times the upper limit of normal and is confirmed on repeat testing.

Scenario 3: MASH Plus Significant Cardiovascular Disease

Patients with MASH frequently carry concurrent atherosclerotic cardiovascular disease (ASCVD). The LDL-C reduction seen with resmetirom is a secondary benefit, but resmetirom does not replace statin therapy. A practical approach is to continue maximally tolerated statin therapy, add resmetirom for the MASH indication, and monitor for the OATP-mediated statin interaction described above. The MAESTRO-NAFLD-1 trial (N=233) confirmed a 26.6% LDL-C reduction with resmetirom 100 mg at 12 weeks in a non-biopsy-confirmed cohort, supporting the lipid benefit as real and reproducible [6].

Pipeline Agents: What Is Coming

Several THR-β agonists remain in development. Understanding their differentiation helps prescribers anticipate future switching decisions.

VK2809

VK2809 (Viking Therapeutics) is a liver-directed THR-β agonist and prodrug. In a Phase 2 trial (N=97) in patients with biopsy-confirmed NASH and dyslipidemia, VK2809 2.5 mg and 10 mg daily for 12 weeks reduced liver fat by 53% and 60% respectively versus 8% for placebo by MRI-PDFF (P<0.001) [7]. A Phase 3 trial (VOYAGE) is ongoing. VK2809 differs from resmetirom structurally in its ester prodrug design, which may further restrict active drug distribution to hepatocytes.

Sobetirome and GC-1

Sobetirome (GC-1, also called sobetirome) was the first highly THR-β-selective compound to reach human trials. Development was halted for NASH after a Phase 1 program, primarily due to CNS penetration concerns in animal models that raised demyelination signals at supratherapeutic doses. It is unlikely to re-enter MASH development, but analogs with reduced CNS penetration remain under investigation in rare lipid disorders [8].

MGL-3196 (Historical)

MGL-3196 was the earlier name for resmetirom during its development phase at Madrigal Pharmaceuticals. Phase 2 data under that identifier showed 37.3% of patients achieving NASH resolution versus 8.5% placebo at 36 weeks in a 125-patient biopsy substudy [9]. Prescribers reviewing older literature will encounter MGL-3196 references as the same molecule.

Safety Profile in Clinical Practice

Gastrointestinal Effects

The most common adverse events in MAESTRO-NASH were nausea (26% resmetirom 100 mg vs. 16% placebo) and diarrhea (29% vs. 19%) [3]. These are dose-dependent and most prominent in the first 4-8 weeks. Starting at 80 mg and titrating after 12 weeks, rather than initiating at 100 mg in patients below 100 kg, reduces early dropout from GI intolerance. Having patients take the tablet with a moderate-fat meal (not a high-fat meal) attenuates peak GI exposure.

Liver Safety

In MAESTRO-NASH, ALT elevations greater than 3 times the upper limit of normal occurred in 5.8% of the resmetirom 100 mg group versus 3.5% of placebo [3]. The absolute excess is modest but meaningful in a population with already-compromised hepatocyte reserve. The FDA label requires discontinuation for confirmed ALT greater than 5 times the upper limit of normal.

Cardiac Safety

As noted, atrial fibrillation rates did not differ significantly between groups in MAESTRO-NASH [3]. Heart rate increased by a mean of 1.4 beats per minute in the 100 mg group versus no change in placebo, consistent with minimal THR-α activation. Bone turnover markers were not significantly different from placebo, supporting the THR-β selectivity in vivo.

Reproductive Considerations

Resmetirom has not been studied in pregnant patients. Animal reproduction studies at exposures approximately 8 times the human AUC showed fetal harm [4]. Prescribers should counsel patients capable of pregnancy to use effective contraception, consistent with the label recommendation.

Monitoring Checklist for the Prescribing Clinician

A structured monitoring protocol reduces avoidable harm and supports documentation for prior authorization renewals.

Before initiation:

• Liver biopsy confirming MASH with F2-F4 fibrosis (required for label-compliant prescribing)
• Baseline AST, ALT, alkaline phosphatase, bilirubin, albumin, INR
• Fasting lipid panel
• List all medications for CYP2C8 and OATP1B1/1B3 interactions
• Confirm absence of decompensated cirrhosis (no ascites, no encephalopathy, no variceal bleeding)
• Pregnancy test where applicable

At 4 weeks:

• AST, ALT (early hepatotoxicity signal)
• Assess GI tolerability; consider antiemetic support if nausea limits adherence

At 12 weeks:

• Full lipid panel (supports dose escalation decision)
• AST, ALT
• Assess weight and metabolic parameters

At 6 months and annually:

• LFTs, lipid panel
• Consider MRI-PDFF for non-invasive steatosis tracking
• Re-evaluate for cirrhosis progression clinically

Positioning Within the Broader MASH Treatment Algorithm

MASH treatment is multimodal. No single drug replaces lifestyle modification, weight management, and control of metabolic comorbidities. The AASLD practice guidance states that "pharmacologic therapy should be considered for patients with MASH and significant fibrosis (stage F2 or greater) who have not achieved sufficient improvement with lifestyle interventions alone" [5].

Resmetirom occupies the first FDA-approved slot in this algorithm. GLP-1 receptor agonists, particularly semaglutide, have shown MASH histologic benefit in Phase 2 (MASH resolution 59% vs. 17% placebo in the NASH semaglutide trial, N=320) [10] and are progressing through Phase 3. Whether resmetirom and GLP-1 agonists will be used in combination or sequentially is an open clinical question. Two ongoing trials, MAESTRO-MASH-OUTCOMES and the Madrigal combination substudy, are designed in part to inform this.

For patients who cannot achieve adequate weight loss with lifestyle modification alone and who have concurrent obesity (BMI <35 kg/m² is not a contraindication, but most MASH patients qualify for anti-obesity pharmacotherapy), adding semaglutide or tirzepatide alongside resmetirom may address both hepatic lipid flux and adipose-driven inflammatory signaling through complementary mechanisms.

Obeticholic acid (OCA), a farnesoid X receptor agonist, was denied full approval by the FDA in June 2023 after interim outcomes data from the REGENERATE trial failed to demonstrate clinical benefit on hard endpoints [11]. This leaves resmetirom as the only approved agent in the MASH pharmacotherapy space as of early 2025.